# OPKO Health, Inc. (OPK) · Edgar & Edgarette company card

> OPKO Health (OPK) saw revenue fall 14.9% in FY2025 to $607 million, operating margin -19.3% against a -3.8% median for pharmaceutical preparations, equity 65.6% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 944809 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/OPK) · [JSON](https://www.pops4.com/boards/company/OPK.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $607M |
| Revenue growth, 1 year | -14.9% |
| Revenue growth per year | -23.5% |
| Operating margin | -19.3% (prior year -21.3%) |
| Net margin | -37.2% |
| Operating cash flow | −$179M |
| Capital spending | $12M |
| Free cash flow | −$191M |
| Cash | $364M |
| Long-term debt | $346M |
| Total assets | $1.9B |
| Total equity | $1.3B |
| Equity ÷ assets | 65.6% |
| Return on equity | -17.8% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -0.79 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Beneish M: -2.8 (below the −1.78 line)
- Health Harbor boat: Rotting at the dock · four or more warning signs · slow and jumpy: growing slower than its size class, with revenue that swings more; operating cash flow was negative; operating loss: a margin of -19.3% in FY2025; revenue is hard to predict: its 80% range is ±26%
- Cash Compass: Fading · slow and jumpy, lagging its peers

## Edgarette's reading

Exposure: revenue $606.9M (FY2025), total debt $346.2M. Experience: revenue down 14.9% on the year, down 23.5% a year over 4 years; operating margin -19.3%, up from -21.3%. Soundness: equity 65.6% of assets, return on equity -17.8%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $389.2M and $657.0M next year (method v4.1: its own 4-year record of growth weighed at 50% against $100M–1B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $340.9M to $754.1M. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -19.3% against a -3.8% median; growth -14.9% against 13.7%.

Range logged 2026-10-16, receipt 108f9872fb5edfb3, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 1, latest 2026-03-19 ([filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526116122/0001193125-26-116122-index.htm))

## Recent filings

- 10-Q · filed 2026-11-04 · [filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526447364/0001193125-26-447364-index.htm)
- 8-K · filed 2026-11-04 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526447357/0001193125-26-447357-index.htm)
- 8-K · filed 2026-10-15 · 1.01 Entry into a Material Definitive Agreement; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526422877/0001193125-26-422877-index.htm)
- 8-K · filed 2026-10-02 · 8.01 Other Events · [filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526412284/0001193125-26-412284-index.htm)
- 8-K · filed 2026-08-14 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526352370/0001193125-26-352370-index.htm)
- 10-Q · filed 2026-07-27 · [filing](https://www.sec.gov/Archives/edgar/data/944809/000119312526318090/0001193125-26-318090-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000944809.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=944809

## Cite

POPS4, Edgar & Edgarette: OPKO Health, Inc. (OPK) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/OPK. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

